{"url_path":"/sec/rkda/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-270560-index.html","accession_number":"0001193125-26-270560","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-270560-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":129,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.\n\nDescription\n\n4.1\n\n[Form of Pre-Funded Warrant](rkda-ex4_1.htm)\n\n4.2\n\n[Form of Series A-1 Preferred Investment Option](rkda-ex4_2.htm)\n\n4.3\n\n[Form of Series A-2 Preferred Investment Option](rkda-ex4_3.htm)\n\nExhibit No.\n\nDescription\n\n4.4\n\n[Form of Placement Agent Preferred Investment Option](rkda-ex4_4.htm)\n\n10.1\n\n[Form Securities Purchase Agreement](rkda-ex10_1.htm)\n\n10.2\n\n[Form of Registration Rights Agreement](rkda-ex10_2.htm)\n\n99.1\n\n \n\n[Press release dated June 11, 2026](rkda-ex99_1.htm)\n\n99.2\n\n \n\n[Press release dated June 12, 2026](rkda-ex99_2.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nARCADIA BIOSCIENCES, INC.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ THOMAS J. SCHAEFER\n\n \n\n \n\n \n\nThomas J. Schaefer, Chief Executive Officer"}